Pay in 4 interest-free payments of $6.16 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Ten-to-twelve-month-old beagle dogs weighing between 9.8 and 12.8 kg were purchased from YaDong Experimental Animal Research Centre, Nanjing, China
In peer-reviewed animal work the concrete numbers are oral doses of roughly 1.442.88 mg/kg given daily to APP/PS1 Alzheimer-model mice over about three months [3] , and low-mg/kg dosing that reversed scopolamine-induced deficits in rodents [1]
Common side effects include: Injection site reactions mild pain, redness, swelling, or bruising at the injection site, typically resolving within a few days Headache usually transient and manageable with standard analgesia Nausea or dizziness particularly in the initial treatment phase Skin reactions including itching, mild rash, or acneiform eruptions Temporary urine discolouration red or orange urine is harmless and expected Diarrhoea or flushing usually mild and self-limiting In patients with severe megaloblastic anaemia, low potassium levels (hypokalaemia) may occur during initial intensive treatment, but this is uncommon in routine maintenance therapy
Most research-context protocols use 3.0 mL of bacteriostatic water for the 80 mg vial, which produces about 26.7 mg/mL total blend concentration
